Shareholders Fight Amgen's Stay Bid

Law360, New York (January 14, 2010, 5:57 PM EST) -- A group of shareholders that claims Amgen Inc. misled investors by concealing the results of a clinical study involving two of its top-selling anemia drugs has challenged the biotech company’s bid to stay the proceedings while its appeal of an order granting class certification is pending.

In a scathing filing Monday in the U.S. District Court for the Central District of California, lead shareholder Connecticut Retirement Plans and Trust Funds said the “drastic step of imposing a stay” hadn’t been justified, arguing instead that merits deposition...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.